The use of pioglitazone and the risk of bladder cancer in people with type 2 diabetes: Nested case-control study

BMJ (Online)

Volumn 344, Issue 7862, 2012, Pages

  Azoulay, Laurent ^a,b   Yin, Hui ^a   Filion, Kristian B ^a,b   Assayag, Jonathan ^a   Majdan, Agnieszka ^c   Pollak, Michael N ^b   Suissa, Samy ^b  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALPHA GLUCOSIDASE INHIBITOR; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLIBENCLAMIDE; GLICLAZIDE; GLIPIZIDE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; GUAR GUM; INSULIN; METFORMIN; ORAL ANTIDIABETIC AGENT; PIOGLITAZONE; ROSIGLITAZONE; SULFONYLUREA DERIVATIVE; ANTIDIABETIC AGENT;

ARTICLE; BLADDER CANCER; CANCER RISK; CASE CONTROL STUDY; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG EXPOSURE; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RISK FACTOR; TREATMENT DURATION; ADULT; AGED; BLADDER TUMOR; CHEMICALLY INDUCED DISORDER; DOSE RESPONSE; MIDDLE AGED; ORAL DRUG ADMINISTRATION; RETROSPECTIVE STUDY;

ADMINISTRATION, ORAL; ADULT; AGED; CASE-CONTROL STUDIES; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; THIAZOLIDINEDIONES; URINARY BLADDER NEOPLASMS;

EID: 84862684037     PISSN: 17561833     EISSN: None     Source Type: Journal    
DOI: 10.1136/bmj.e3645     Document Type: Article

References (38)

1. Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005;366:1279-89. (Pubitemid 41416583)
2. Lincoff AM, Wolski K, Nicholls SJ, Nissen SE. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA 2007;298:1180-8. (Pubitemid 47403104)
3. Piccinni C, Motola D, Marchesini G, Poluzzi E. Assessing the association of pioglitazone use and bladder cancer through drug adverse event reporting. Diabetes Care 2011;34:1369-71.
4. Lewis JD, Ferrara A, Peng T, Hedderson M, Bilker WB, Quesenberry CP Jr, et al. Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study. Diabetes Care 2011;34:916-22.
5. Caisse nationale de l'assurance maladie. Risque de cancer de la vessie chez les personnes diabétiques traitées par pioglitazone en France: une étude de cohorte sur les données du SNIIRAM et du PMSI. Agence française de sécurité sanitaire des produits de santé. 2011. www.afssaps.fr/var/afssaps-site/storage/original/ application/b42a6bf9a1b63c3dbec7388d3914687b.pdf.
6. Dormandy J, Bhattacharya M, van Troostenburg de Bruyn AR. Safety and tolerability of pioglitazone in high-risk patients with type 2 diabetes: an overview of data from PROactive. Drug Saf 2009;32:187-202.
7. Hillaire-Buys D, Faillie JL, Montastruc JL. Pioglitazone and bladder cancer. Lancet 2011;378:1543-4.
8. Questions and answers on the review of pioglitazone-containing medicines (Actos, Glustin, Competact, Glubrava and Tandemact). European Medicines Agency. 2011. www.ema.europa.eu/docs/en-GB/document-library/Medicine-QA/2011/07/ WC500109179.pdf.
9. Food and Drug Administration. FDA Drug Safety Communication: update to ongoing safety review of Actos (pioglitazone) and increased risk of bladder cancer. FDA Drug Safety Communication. 2011. www.fda.gov/Drugs/DrugSafety/ ucm259150.htm#aihp.
10. Health Canada. Health Canada reviewing diabetes drug pioglitazone (Actos) and potential risk of bladder cancer. Health Canada. 2011. www.hc-sc.gc.ca/ahc- asc/media/advisoriesavis/-2011/2011-79-eng.php.
11. Chang CH, Lin JW, Wu LC, Lai MS, Chuang LM, Chan KA. Association of thiazolidinediones with liver cancer and colorectal cancer in type 2 diabetes mellitus. Hepatology 2011;55:1462-72.
12. Tseng CH. Pioglitazone and bladder cancer: a population-based study of Taiwanese. Diabetes Care 2012;35:278-80.
13. Walley T, Mantgani A. The UK General Practice Research Database. Lancet 1997;350:1097-9. (Pubitemid 27437871)
14. Garcia Rodriguez LA, Perez GS. Use of the UK General Practice Research Database for pharmacoepidemiology. Br J Clin Pharmacol 1998;45:419-25. (Pubitemid 28227341)
15. Jick H, Jick SS, Derby LE. Validation of information recorded on general practitioner based computerised data resource in the United Kingdom. BMJ 1991;302:766-8.
16. Lawrenson R, Williams T, Farmer R. Clinical information for research; the use of general practice databases. J Public Health Med 1999;21:299-304. (Pubitemid 29446069)
17. Lawrenson R, Todd JC, Leydon GM, Williams TJ, Farmer RD. Validation of the diagnosis of venous thromboembolism in general practice database studies. Br J Clin Pharmacol 2000;49:591-6. (Pubitemid 30326559)
18. Jick SS, Kaye JA, Vasilakis-Scaramozza C, Garcia Rodriguez LA, Ruigomez A, Meier CR, et al. Validity of the general practice research database. Pharmacotherapy 2003;23:686-9. (Pubitemid 36539051)
19. Suissa S. Novel approaches to pharmacoepidemiology study design and statistical analysis. In: Strom B, ed. Pharmacoepidemiology. 4th ed. Wiley; 2005:811-29.
20. Essebag V, Platt RW, Abrahamowicz M, Pilote L. Comparison of nested case-control and survival analysis methodologies for analysis of time-dependent exposure. BMC Med Res Methodol 2005;5:5.
21. Essebag V, Genest J Jr, Suissa S, Pilote L. The nested case-control study in cardiology. Am Heart J 2003;146:581-90. (Pubitemid 37281701)
22. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373-83. (Pubitemid 17055592)
23. Khan NF, Perera R, Harper S, Rose PW. Adaptation and validation of the Charlson Index for Read/OXMIS coded databases. BMC Fam Pract 2010;11:1.
24. Cancer Research UK. Bladder cancer (C67), average number of new cases per year and age-specific incidence rates, UK, 2006-2008. Cancer Research UK. 2012. http://info.cancerresearchuk.org/cancerstats/types/bladder/incidence/.
25. Larsson SC, Orsini N, Brismar K, Wolk A. Diabetes mellitus and risk of bladder cancer: a meta-analysis. Diabetologia 2006;49:2819-23. (Pubitemid 44730282)
26. Ray WA. Evaluating medication effects outside of clinical trials: new-user designs. Am J Epidemiol 2003;158:915-20. (Pubitemid 37323253)
27. Kahn BB, McGraw TE. Rosiglitazone, PPARgamma, and type 2 diabetes. N Engl J Med 2010;363:2667-9.
28. Choi JH, Banks AS, Kamenecka TM, Busby SA, Chalmers MJ, Kumar N, et al. Antidiabetic actions of a non-agonist PPARgamma ligand blocking Cdk5-mediated phosphorylation. Nature 2011;477:477-81.
29. Yoshimura R, Matsuyama M, Segawa Y, Hase T, Mitsuhashi M, Tsuchida K, et al. Expression of peroxisome proliferator-activated receptors (PPARs) in human urinary bladder carcinoma and growth inhibition by its agonists. Int J Cancer 2003;104:597-602. (Pubitemid 36337259)
30. Nakashiro KI, Hayashi Y, Kita A, Tamatani T, Chlenski A, Usuda N, et al. Role of peroxisome proliferator-activated receptor gamma and its ligands in non-neoplastic and neoplastic human urothelial cells. Am J Pathol 2001;159:591-7. (Pubitemid 32751089)
31. Guan YF, Zhang YH, Breyer RM, Davis L, Breyer MD. Expression of peroxisome proliferator-activated receptor gamma (PPARgamma) in human transitional bladder cancer and its role in inducing cell death. Neoplasia 1999;1:330-9.
32. Suzuki S, Arnold LL, Pennington KL, Kakiuchi-Kiyota S, Wei M, Wanibuchi H, et al. Effects of pioglitazone, a peroxisome proliferator-activated receptor gamma agonist, on the urine and urothelium of the rat. Toxicol Sci 2010;113:349-57.
33. Sato K, Awasaki Y, Kandori H, Tanakamaru ZY, Nagai H, Baron D, et al. Suppressive effects of acid-forming diet against the tumorigenic potential of pioglitazone hydrochloride in the urinary bladder of male rats. Toxicol Appl Pharmacol 2011;251:234-44.
34. Dominick MA, White MR, Sanderson TP, Van VT, Cohen SM, Arnold LE, et al. Urothelial carcinogenesis in the urinary bladder of male rats treated with muraglitazar, a PPAR alpha/gamma agonist: evidence for urolithiasis as the inciting event in the mode of action. Toxicol Pathol 2006;34:903-20. (Pubitemid 46011143)
35. Edwards KL, Alvarez C, Irons BK, Fields J. Third-line agent selection for patients with type 2 diabetes mellitus uncontrolled with sulfonylureas and metformin. Pharmacotherapy 2008;28:506-21. (Pubitemid 351466462)
36. MacKenzie T, Zens MS, Ferrara A, Schned A, Karagas MR. Diabetes and risk of bladder cancer: evidence from a case-control study in New England. Cancer 2011;117:1552-6.
37. Benoit SR, Fleming R, Philis-Tsimikas A, Ji M. Predictors of glycemic control among patients with type 2 diabetes: a longitudinal study. BMC Public Health 2005;5:36.
38. Van Staa TP, Patel D, Gallagher AM, de Bruin ML. Glucose-lowering agents and the patterns of risk for cancer: a study with the General Practice Research Database and secondary care data. Diabetologia 2012;55:654-65.